via Dalal Street

[via-dalalstreet]

(via First Global report on diabetes by WHO-With Latest INDIA SPECIFIC Data.)

[via-dalalstreet]

Infliximab Biosimilar- Inflectra approved by FDA.

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. INFLECTRA is now the first and only bio…

[via-dalalstreet]

These Small caps doubled when you were counting losses.

These Small caps doubled when you were counting losses.

The market ended FY16 on a muted note, with the benchmark indices shedding more than 9 per cent led by losses in capital goods, metal, power, banking, pharma, auto stocks, among others.

The S&P BSE Sensex plunged 9.3 per cent led by losses in BHELBSE 2.77 % (down 51%), ONGC (down 30%), Tata MotorsBSE -1.75 % (down 29%), L&T (down 29%), Cipla (down 27%), SBI (down 27%).

Some small cap stocks gave…

View On WordPress

[via-dalalstreet]

Cupid receives New order.

Cupid Ltd. Indian condom maker is in sweet spot with Indian investors from last year.

Cupid Ltd has give more than 1000% return in 2015.In 2016, though it has cooled off somehow. Today Mr. Omprakash Garg, head of Cupid Ltd announced 2.95 CR order from DKT India. Order is of male condom.

About DKT India

Delivering quality public health services in family planning and HIV/AIDS prevention in…

View On WordPress

[via-dalalstreet]

Kellton tech received listing permission from NSE. 01 March 2016 Kellton Tech Solutions Ltd has informed BSE that the Company has received listing permission from NSE vide letter dated February 29, 2016 pursuant to which equity shares of the Company will be listed and admitted to dealings w.e.f. March 02, 2016.

[via-dalalstreet]

1 March 2016 FII / FPI activity FII F&O Stats as on 1 Mar'16(Rs Total BUY : + 6153 Index Future : + 706…

[via-dalalstreet]

Sensex posts biggest single day gains after budget.

Sensex posts biggest single day gains after budget.

01 March 2016

Sensex climbed up 777 points to give big salute to FM Arun Jaitely.

The Nifty50 reclaimed its crucial psychological mark of 7,200. The index surged 235.25 points, or 3.37 per cent, to close at 7,222.30.

The gains seen on  indices were due to buying in interest-rate sensitive stocks as the commitment by the FM Arun Jaitley to meet the fiscal deficit target for FY16 raised hopes of a…

View On WordPress

[via-dalalstreet]

Mangalam Drugs & Organics Ltd "Investor Presentation - January 2016".

Mangalam Drugs & Organics Ltd “Investor Presentation – January 2016”.

Mangalam Drug has come up with investor presentation ffor Jan 2016.

  Source:

http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/A181D847_2C62_472B_B2B5_D926306D0ABD_124459.pdf

 View On WordPress

[via-dalalstreet]

Britannia shows Great Strength..#Q3Fy16

Britannia Industries said its third quarter profit grew 51.2 cent to Rs 207.59 crore and sales up by 10.17 per cent to Rs 2,240.22 crore as it reached out to more customers across states.

The company had reported profit of Rs 137.28 crore and revenue of Rs 2,033.28 crore in the October to December quarter of 2014.

“Our strategy of focussing on execution and commercialising potential consumption…

View On WordPress

[via-dalalstreet]

Stocks in Focus #10 Feb 2016

Stocks in Focus #10 Feb 2016

Stocks likely to be in limelight today.

🔹Hindalco Industries Ltd:

The company on Tuesday said its standalone net profit fell 89% in the December quarter on lower price realizations as aluminium prices continued to slide in the global commodity slowdown.

🔹Essar Oil Ltd:

Essar Oil’s net profit soared to Rs 364 crore in the third quarter if 2015-16 from Rs 52 crore a year ago despite a decline in…

View On WordPress

[via-dalalstreet]

Aurobindo Pharma rises on receiving USFDA approval for Isosulfan Blue Injection Aurobindo Pharma is currently trading at Rs. 771.00, up by 4.45 points or 0.58% from its previous closing of Rs.

[via-dalalstreet]

3rd Feb-Today’s Key Result.

[via-dalalstreet]

Aurobindo Pharma receives USFDA Approval for Celecoxib Capsules 2 Feb 2016 Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg.

[via-dalalstreet]

Aurobindo Pharma receives USFDA Approval for Levetiracetam Injection 2 Feb 2016 Aurobindo Pharma Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Levetiracetam Injection USP, 500 mg/5 mL (100 mg/mL) single-dose vials.

[via-dalalstreet]

Ajanta Pharma Posts Good Quarterly Show.

Ajanta Pharma Posts Good Quarterly Show.

Mumbai based Mid Cap Pharmaceutical Company Ajanta Pharma declared good set of Q3FY16 numbers.

Here are few highlights of the result:

Co. is gaining good market share in regulated market like USA. They are able to increase their business substantially.

Co is investing heavily in R&D to have future growth secured. About 5% of net sales. In 9m FY16, the total R&D expense (excluding capex) was 70cr…

View On WordPress

[via-dalalstreet]

Kellton Tech- Management Confident of achieving FY16 600Cr revenue guidance.

Kellton Tech- Management Confident of achieving FY16 600Cr revenue guidance.

Kellton Tech is a full-grown software development company, offering end-to-end IT solutions, strategic technology consulting and product development services in Web, SMAC (Social, Mobile, Analytics, Cloud), ERP-BPM, and IoT space. The company is listed on India’s largest stock exchange BSE [Code: KELLTONTEC; BOM: 519602] and is ISO 9001:2008 and CMMi Level 3 certified.

Founded in 1993,…

View On WordPress

[via-dalalstreet]

Kellton Tech Dec quarter Net up 2-fold at Rs 10 crore

Kellton Tech Dec quarter Net up 2-fold at Rs 10 crore http://economictimes.indiatimes.com/markets/stocks/earnings/kellton-tech-dec-quarter-net-up-2-fold-at-rs-10-crore/articleshow/50793869.cms

View On WordPress